EFFECTIVENESS OF ADDITION OF METFORMIN TO STATIN THERAPY FOR PRODIABETOGENIC CHANGES CORRECTION IN PATIENTS WITH ARTERIAL HYPERTENSION AND OBESITY

Abstract

The aim: to study the effectiveness of adding metformin to statin therapy to correct prodiabetogenic changes in patients with arterial hypertension (AH) and abdominal obesity (AO). Materials and methods. We examined 65 patients with 2-3 degrees of AH in combination with AO of I-II degrees, atherogenic dyslipidemia and insulin resistance (IR) aged 47-59 yrs: group 1 – 35 patients who were treated with statins (atorvastatin) against the background of standard combinations of antihypertensive drugs, metformin was added; group 2 – 30 patients who did not receive metformin. The examination included generally accepted methods. Statistical data analysis was carried out using standard methods using Microsoft Excel 7.0 and SPSS 19.0 application packages. Results. The addition of metformin to atorvastatin against the background of standard antihypertensive therapy and recommendations for the normalization of lifestyle allowed a significant reduction in IR and the incidence of prediabetes in hypertensive patients with AO after 16 weeks of treatment. In patients who did not receive metformin, there was no decrease in these indicators. In the group of patients who used metformin, a significantly higher frequency of achieving target blood pressure levels was revealed than in the group of patients in whom this drug was not used. Conclusions. The effectiveness of the use of the insulin sensitizer metformin for the correction of pro-diabetogenic changes associated with statin therapy in patients with AH, which occurs against the background of AO, atherogenic dyslipidemia, and IR, has been shown.